TY - JOUR
T1 - Systematic review
T2 - brain metastases from colorectal cancer--Incidence and patient characteristics
AU - Christensen, Troels Dreier
AU - Spindler, Karen-Lise Garm
AU - Palshof, Jesper Andreas
AU - Nielsen, Dorte Lisbet
PY - 2016/4/1
Y1 - 2016/4/1
N2 - BACKGROUND: Brain metastases (BM) from colorectal cancer (CRC) are a rare event. However, the implications for affected patients are severe, and the incidence has been reported to be increasing. For clinicians, knowledge about the characteristics associated with BM is important and could lead to earlier diagnosis and improved survival.METHOD: In this paper, we describe the incidence as well as characteristics associated with BM based on a systematic review of the current literature, following the PRISMA guidelines.RESULTS: We show that the incidence of BM in CRC patients ranges from 0.6 to 3.2%. BM are a late stage phenomenon, and young age, rectal primary and lung metastases are associated with increased risk of developing BM. Molecular markers such as KRAS, BRAF, NRAS mutation as well as an increase in CEA and CA19.9 levels are suggested predictors of brain involvement. However, only KRAS mutations are reasonably well investigated and associated with an increased risk of BM.CONCLUSION: The incidence of BM from CRC is 0.6 to 3.2% and did not seem to increase over time. Development of BM is associated with young age, lung metastases, rectal primary and KRAS mutation. Increased awareness of brain involvement in patients with these characteristics is necessary.
AB - BACKGROUND: Brain metastases (BM) from colorectal cancer (CRC) are a rare event. However, the implications for affected patients are severe, and the incidence has been reported to be increasing. For clinicians, knowledge about the characteristics associated with BM is important and could lead to earlier diagnosis and improved survival.METHOD: In this paper, we describe the incidence as well as characteristics associated with BM based on a systematic review of the current literature, following the PRISMA guidelines.RESULTS: We show that the incidence of BM in CRC patients ranges from 0.6 to 3.2%. BM are a late stage phenomenon, and young age, rectal primary and lung metastases are associated with increased risk of developing BM. Molecular markers such as KRAS, BRAF, NRAS mutation as well as an increase in CEA and CA19.9 levels are suggested predictors of brain involvement. However, only KRAS mutations are reasonably well investigated and associated with an increased risk of BM.CONCLUSION: The incidence of BM from CRC is 0.6 to 3.2% and did not seem to increase over time. Development of BM is associated with young age, lung metastases, rectal primary and KRAS mutation. Increased awareness of brain involvement in patients with these characteristics is necessary.
KW - Age Factors
KW - Brain Neoplasms
KW - Colorectal Neoplasms
KW - Female
KW - GTP Phosphohydrolases
KW - Genetic Association Studies
KW - Humans
KW - Lung Neoplasms
KW - Male
KW - Membrane Proteins
KW - Mutation
KW - Prognosis
KW - Proto-Oncogene Proteins B-raf
KW - Proto-Oncogene Proteins p21(ras)
KW - Risk Factors
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
KW - Review
U2 - 10.1186/s12885-016-2290-5
DO - 10.1186/s12885-016-2290-5
M3 - Journal article
C2 - 27037031
SN - 1471-2407
VL - 16
SP - 260
JO - B M C Cancer
JF - B M C Cancer
ER -